Table 1.
Demographics, comorbidities, serum laboratory values, and noninvasive fibrosis scores for all cancer patients and stratified by chemotherapy treatment
| Variable | Total (n = 279) | Chemotherapy (n = 117) | No chemotherapy (n = 162) | p |
|---|---|---|---|---|
| Demographics and comorbidities | ||||
| Age (years), mean ± SE | 59.1 ± 0.7 | 59.2 ± 1.1 | 59.0 ± 0.9 | 0.90 |
| Female, n (%) | 156 (55.9) | 64 (54.7) | 92 (56.8) | 0.73 |
| Ethnicity, n (%) | 0.02 | |||
| White | 186 (66.7) | 87 (74.4) | 99 (61.1) | |
| Black | 66 (23.7) | 17 (14.5) | 49 (30.3) | |
| Hispanic | 10 (3.6) | 4 (3.4) | 6 (3.7) | |
| Asian | 10 (3.6) | 4 (3.4) | 6 (3.7) | |
| Native American | 4 (1.4) | 2 (1.7) | 2 (1.2) | |
| Body mass index (kg/m2), mean ± SE | 31.0 ± 0.5 | 30.2 ± 0.7 | 31.6 ± 0.7 | 0.17 |
| Hypertension, n (%) | 194 (69.5) | 78 (66.7) | 116 (71.6) | 0.37 |
| Diabetes mellitus, n (%) | 103 (36.9) | 33 (28.2) | 70 (43.2) | 0.01 |
| Dyslipidemia, n (%) | 127 (45.5) | 51 (43.6) | 76 (46.9) | 0.58 |
| Metabolic syndrome, n (%) | 105 (37.6) | 35 (29.9) | 70 (43.2) | 0.02 |
| Cancer type | <0.01 | |||
| Gastrointestinal, n (%) | 123 (44.1) | 67 (57.3) | 56 (34.6) | |
| Soft tissue, n (%) | 77 (27.6) | 25 (21.4) | 52 (32.1) | |
| Genitourinary, n (%) | 45 (16.1) | 13 (11.1) | 32 (20.0) | |
| Other, n (%) | 34 (12.2) | 12 (10.3) | 22 (13.6) | |
| Serum laboratory values | ||||
| Alanine aminotransferase (U/L), mean ± SE | 38.8 ± 2.1 | 37.8 ± 3.0 | 39.5 ± 2.9 | 0.68 |
| Aspartate aminotransferase (U/L), mean ± SE | 36.9 ± 1.9 | 35.4 ± 2.3 | 38.0 ± 2.9 | 0.50 |
| Total bilirubin (mg/dL), mean ± SE | 0.76 ± 0.04 | 0.76 ± 0.08 | 0.77 ± 0.03 | 0.90 |
| Alkaline phosphatase (U/L), mean ± SE | 107.0 ± 5.6 | 108.9 ± 7.8 | 105.7 ± 8.0 | 0.77 |
| Albumin (mg/dL) | 3.53 ± 0.04 | 3.64 ± 0.05 | 3.44 ± 0.07 | 0.02 |
| Creatinine (mg/dL), mean ± SE | 0.91 ± 0.02 | 0.88 ± 0.02 | 0.93 ± 0.03 | 0.17 |
| Hemoglobin (g/dL), mean ± SE | 12.2 ± 0.2 | 12.2 ± 0.2 | 12.2 ± 0.2 | 0.95 |
| Hematocrit (%), mean ± SE | 36.5 ± 0.3 | 36.6 ± 0.5 | 36.5 ± 0.4 | 0.85 |
| Platelets (thousand/μL), mean ± SE | 252.0 ± 7.0 | 219.9 ± 8.0 | 275.7 ± 10.3 | <0.01 |
| Diagnostic radiologic imaging | 0.94 | |||
| Computed tomography, n (%) | 260 (93.2) | 109 (93.2) | 151 (93.2) | |
| Ultrasound, n (%) | 15 (5.4) | 5 (5.1) | 9 (5.6) | |
| Magnetic resonance imaging, n (%) | 4 (1.4) | 2 (1.7) | 2 (1.2) | |
| Noninvasive fibrosis scores | ||||
| APRI, mean ± SE | 0.498 ± 0.037 | 0.531 ± 0.043 | 0.475 ± 0.056 | 0.43 |
| Low probability of fibrosis, APRI | 197 (66.3) | 75 (64.1) | 122 (75.3) | 0.04 |
Specified p values are from comparisons between patients treated with and without chemotherapy
SE standard error, APRI AST-to-platelet ratio index